WASHINGTON — It’s arguably the most cutting-edge and potentially lucrative area of biomedical science and now, to protect their investments, companies commercializing CRISPR genome editing technology are looking to shore up their Washington bonafides.

But unlike their comrades in the conventional drug world, CRISPR lobbyists aren’t blitzing every office on Capitol Hill with a slate of pro-industry proposals. The goal is more understated: to make sure the companies with experimental treatments just now entering the clinic are unimpeded by government bureaucracies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy